Latest Breaking News On - Cardiovascular health outcomes analysis - Page 1 : comparemela.com

Currax Pharmaceuticals: CONTRAVE(R)/MYSIMBA(R) demonstrates no increased risk in major adverse cardiac events in a large, long-term real-world evidence study

Currax Pharmaceuticals LLC(Currax) today announced top-line results from a Cardiovascular Health Outcomes Analysis (HOA). This study evaluated the cardiovascular safety of CONTRAVE(R)/MYSIMBA(R), a weight management drug. The real-world study

Michael kyleGeorge hamptonCardiovascular health outcomes analysisDrug administrationCurrax pharmaceuticalsEuropean medicines agencyHealth outcomes analysisEuropean unionChief medicalCurrax presidentHealth outcomesEuropean economic area

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® demonstrates no increased risk in major adverse cardiac events in a large, long-term real-world evidence study

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® demonstrates no increased risk in major adverse cardiac events in a large, long-term real-world evidence study
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Michael kyleGeorge hamptonIndiens wirtschaftIhre chancenEuropean medicines agencyDrug administrationEuropean unionPrnewswire currax pharmaceuticalsCardiovascular health outcomes analysisHealth outcomes analysisChief medicalCurrax presidentEuropean economic areaDer indienDie highlights